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OBJECTIVES This study investigated outcomes in patients with cardiogenic shock and severe renal
dysfunction treated with ventricular assist devices (VAD) as a bridge to cardiac transplanta-
tion.
BACKGROUND Previous reports have documented poor survival in patients with cardiogenic shock and severe
renal dysfunction treated with VAD.
METHODS We surveyed 215 consecutive patients who received a VAD from 1992 to 2000 and selected
patients who had a serum creatinine 3.0 mg/dl at the time of VAD placement.
Demographic, laboratory, and clinical outcome data were collected.
RESULTS Eighteen patients met the inclusion criteria. Mean serum creatinine at the time of VAD
placement was 4.0  0.7 mg/dl (range 3.0 to 5.2 mg/dl). Seven patients required temporary
renal support with continuous venovenous hemodialysis (CVVHD). Eleven patients under-
went cardiac transplantation. At six months post-transplantation, mean serum creatinine was
2.0  0.6 mg/dl (range 1.3 to 3.5 mg/dl). None of the transplanted patients required
subsequent renal support. Seven patients died with a VAD before transplantation. Three died
early (1 month) after VAD placement, and all three required CVVHD until death. Four
patients survived for 1 month after VAD placement; all four had resolution of renal
dysfunction with mean serum creatinine of 1.9  1.2 mg/dl (range 0.8 to 3.6 mg/dl) without
the need for renal support. Overall 30-day and six-month survival after VAD placement,
survival to transplantation, and survival one year post-transplantation were similar to patients
without severe renal dysfunction.
CONCLUSIONS Contemporary use of VAD leads to resolution of severe renal dysfunction in most cardiogenic
shock patients and comparable long-term outcomes to patients without renal
dysfunction. (J Am Coll Cardiol 2003;41:381–5) © 2003 by the American College of
Cardiology Foundation
In patients with cardiogenic shock refractory to conven-
tional therapy, cardiac transplantation has been shown to be
a highly effective treatment. However, because of donor
scarcity, progressive heart failure, and difficulties in cross-
matching, many patients are at a significant risk of dying
before a donor organ becomes available (1). In this setting,
a strategy of using mechanical circulatory support with
ventricular assist devices (VAD) as a “bridge” to cardiac
transplantation has become an established therapy (1).
These Food and Drug Administration–approved devices are
clearly able to provide partial or total support for cardiac
function in critically ill patients until cardiac transplantation
can occur. However, VAD are expensive, technically sophis-
ticated, and associated with their own inherent complica-
tions such as mechanical failure, infection, and thrombo-
embolism. Therefore, proper selection of patients who
would derive the most benefit from this support is essential.
Patients in cardiogenic shock are at risk of developing
other concomitant organ failure. Renal dysfunction is par-
ticularly ominous because it is associated with a dramatic
increase in mortality (2). In fact, previous outcomes with the
use of VAD in patients with cardiogenic shock and severe
renal dysfunction have been overwhelmingly dismal (3–6).
Kanter et al. (3) initially reported, in 1987, a 100% mortality
in patients requiring dialysis in the peri-implantation pe-
riod. In a risk factor score model for mortality after VAD
placement, Oz et al. (4) showed that renal dysfunction
(defined as a urine output 30 ml/h) was the most
significant risk factor for mortality, increasing it by 3.9
times. In a series of 55 patients with acute renal failure and
cardiogenic shock treated with VAD at the German Heart
Institute, six-month survival was only 7% and survival to
transplantation was only 11% (5). Finally, data from the
European registry of mechanical circulatory support indi-
cated that renal failure was one of the most powerful
predictors of both short-term and long-term mortality (6).
These ominous results have led some to recommend that
renal failure is an absolute contraindication to VAD place-
ment (7).
Nonetheless, a number of small studies suggest that renal
failure can be reversed with mechanical support. Burnett et
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al. (8) showed in a study of six patients that renal failure
often resolved with VAD placement, and that these patients
could then be successfully transplanted. Our institution
previously reported a 40% survival in patients with renal
failure (defined as the need for continuous renal replacement
therapy) and subsequent recovery of renal function in the
surviving patients (9). Because of this continuing contro-
versy, we examined our recent experience with 18 patients
having severe renal dysfunction and cardiogenic shock
treated with VAD insertion as a bridge to cardiac trans-
plantation.
METHODS
We surveyed 215 consecutive patients who received a VAD
from 1992 to 2000 at our institution according to standard
criteria (10,11). We then selected patients who had a serum
creatinine 3.0 mg/dl at the time of VAD placement.
Demographic, laboratory, and clinical outcome data were
collected. A VAD registry (Unified Transplant Database) is
maintained at the Cleveland Clinic Foundation to facilitate
analysis of patient outcomes. The Cleveland Clinic Foun-
dation’s institutional review board has approved research
based on this Unified Transplant Database.
All patients with renal failure had formal nephrology
consultation. Urinalysis was performed and microscopic
examination was conducted in all patients by the nephrol-
ogist. Renal ultrasound to rule out obstruction and docu-
ment kidney size was performed in all patients. If patients
had significant proteinuria on urinalysis, 24-h urine was
collected to measure the level of protein excretion. If there
were disparities in kidney size, either renal duplex ultra-
sound or renal magnetic resonance angiography was per-
formed. Patients with significant proteinuria or small kid-
neys were excluded from consideration for VAD placement.
Peritransplant management consisted of avoidance of
calcineurin antagonists, administration of cytolytic therapy
early after transplantation, and initiation of cyclosporine
both at reduced dose and at a later time after transplanta-
tion. Renal dose dopamine was administered as long as it
did not cause tachyarrhythmias.
The treatment groups were compared using a Pearson
chi-square test (gender, overall 6-month survival, and sur-
vival to transplantation), or if expected cell counts were
small, a Fisher exact test (diabetes mellitus; extracorporeal
membrane oxygenation pre-VAD; continuous venovenous
hemodialysis [CVVHD] pre-VAD; overall 30-day survival;
and 30-day, 6-month, and 1-year survival post-
transplantation). Analysis of variance f test results were used
for continuous variables. Values are listed as mean  SD.
RESULTS
Of 215 consecutive patients, 197 patients had a serum
creatinine of 3.0 mg/dl; their demographic characteristics
are outlined in Table 1.
Eighteen patients met the search criteria of serum creat-
inine3.0 mg/dl (Table 1). This group consisted of 14 men
and 4 women. The mean age was 53  12 years (range 33
to 68 years). The etiology of cardiogenic shock was ischemic
in 12 patients and nonischemic in six patients. Chronic
renal insufficiency (serum creatinine 1.5 mg/dl) was noted
in eight patients. One patient was on hemodialysis before
VAD insertion for approximately one year. Further demo-
graphics are listed in Table 1.
The Thoratec HeartMate (Thoratec Corp., Pleasanton,
California) device was implanted in 11 patients, and seven
patients received the Novacor left ventricular assist system
(World Heart Corp., Ottawa, Canada) device. The median
time between the onset of renal failure and placement of a
VAD was three days (range 0 to 370 days). The mean serum
creatinine at the time of VAD placement was 4.0  0.7
mg/dl (range 3.0 to 5.2 mg/dl). Seven patients required
temporary renal support with CVVHD during the peri-
implantation period; four patients had it before VAD
placement, and three patients had it after VAD placement.
The mean time for dialysis support was 23 26 days (range
1 to 70 days).
Seven VAD patients died before transplantation. In this
group, three patients died early (1 month) after VAD
placement. All required renal support until the time of death
(Fig. 1). Four patients survived for more than one month
after VAD placement but ultimately died before transplan-
tation; all four had resolution of severe renal dysfunction
with mean serum creatinine of 1.9  1.2 mg/dl at the time
of death (range 0.8 to 3.6 mg/dl) without the need for
Abbreviations and Acronyms
CVVHD  continuous venovenous hemodialysis
VAD  ventricular assist device(s)
Table 1. Baseline Characteristics
Characteristic
Non-Renal
Failure
(n  197)
Renal
Failure
(n  18)
Age (yrs) 55  11 53  12*
Male 170/197 (86%) 14/18 (78%)*
Diabetes mellitus 26/197 (13%) 1/18 (6%)*
ECMO pre-VAD 37/197 (19%) 7/18 (39%)†
CVVHD pre-VAD 2/197 (1%) 4/18 (22%)‡
Time from hospital admit
to VAD (days)
11.6  19.4 11.8  10.3*
Serum creatinine at VAD
placement (mg/dl)
1.6  0.6 4.0  0.7‡
*p  NS; †p  0.05; ‡p  0.001.
CVVHD  continuous venovenous hemodialysis; ECMO  extracorporeal
membrane oxygenation; VAD  ventricular assist device.
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further renal support (Fig. 1). In these patients, the cause of
death was sepsis or stroke.
Eleven patients subsequently underwent cardiac trans-
plantation. Serum creatinine had fallen from 4.1  0.6
mg/dl at VAD placement to 1.6  0.5 mg/dl at transplan-
tation (Fig. 1). This improvement persisted at both three-
month and six-month follow-up (Fig. 1). No patient re-
quired renal support therapy after transplantation. Of note,
the patient on hemodialysis for one year before VAD
placement had a serum creatinine of 2.1 mg/dl at six months
post-transplantation.
Overall 30-day survival after VAD placement, six-month
survival after VAD placement, survival to transplantation
(Fig. 2), and survival 30 days, 6 months, and 1 year
post-transplantation were similar in patients without renal
failure and those with renal failure (Fig. 3).
DISCUSSION
In patients with severe renal dysfunction complicating
cardiogenic shock, placement of a VAD as a bridge to
cardiac transplantation is generally associated with overall
excellent recovery of renal function in our series. No patient
who ultimately received cardiac transplantation required
long-term renal support, and transplantation was associated
with excellent long-term outcomes. Even in patients who
Figure 1. Change in serum creatinine with ventricular assist device (VAD) placement in VAD patients who died early (1 month), late (1 month), and
those who survived to cardiac transplantation. The three patients who died early were on continuous venovenous hemodialysis at the time of death. TX 
transplantation.
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did not receive transplantation, long-term (1 month)
survival with a VAD led to resolution of severe renal
dysfunction in all cases despite eventual mortality from
other causes. Only in those patients not transplanted who
had early (1 month) mortality did severe renal dysfunction
and the need for renal replacement therapy persist.
Multiple factors may explain the differences in outcomes
between our results and those of other investigators. One
potential factor is that the definition of renal failure differs
greatly between studies. Specifically, the need for renal
replacement therapy defined renal failure in some studies,
whereas other studies used urine output or elevations in
serum creatinine. A series of patients needing renal replace-
ment therapy may select a much sicker population that has
developed irreversible end-organ damage. However, more
than half of our patients who required renal replacement
therapy were able to survive to transplantation. Thus, the
requirement for dialysis support does not explain the differ-
ence in outcomes.
The type of renal replacement therapy used may have an
impact on outcomes. Most of the studies documenting poor
outcomes used either hemodialysis or hemofiltration as their
primary means of renal replacement therapy. These meth-
ods of renal replacement therapy are known to be hemody-
namically stressful and often difficult to use in these critically
ill patients. In Kanter’s study, for example, despite early
institution of hemodialysis, adequate renal support was
unable to be maintained (3). The use of continuous renal
replacement therapy may be an attractive alternative because
it has been shown to be an effective and well-tolerated
therapy in hemodynamically unstable patients (12–14). Our
institution has previously documented excellent manage-
ment of fluid status, uremia, and electrolytes when contin-
uous renal replacement therapy is used to treat acute renal
failure in patients with VAD (9). Therefore, our exclusive
use of continuous renal replacement therapy rather than
hemodialysis may have contributed to our improved out-
comes.
Yet, the majority of our patients did not require any renal
replacement therapy. What explains their excellent out-
come? The hemodynamic improvements after VAD inser-
tion have been well described with dramatic improvements
Figure 2. Comparison of 30-day survival, 6-month survival, and survival to cardiac transplantation in ventricular assist device patients according to the
absence or presence of severe renal failure (RF).
Figure 3. Comparison of 30-day, 6-month, and one-year survival post-transplantation in ventricular assist device patients who survived to cardiac
transplantation according to the absence or presence of severe renal failure (RF). TX  Transplantation.
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in cardiac output and significant decreases in elevated filling
pressures (15). By rapidly improving cardiac function in
these critically ill patients, VAD likely lead to reversal of
renal hypoperfusion and a subsequent stabilization or im-
provement of renal function. Bank et al. (16) have shown
that VAD placement, when compared with standard ino-
tropic therapy, is associated with a reduction in the risk of
developing acute renal failure, implying a renal protective
effect of mechanical support. In addition, VAD placement
in patients with renal failure has been shown to improve
renal function, and in one nonrandomized study was shown
to be associated with a dramatic improvement in mortality
when compared with standard non-mechanical therapy
(17). The improvements in renal function are likely ex-
plained by not only improved cardiac function but also
subsequent correction of the abnormal neurohormonal mi-
lieu found in cardiogenic shock. James et al. (18) have
shown that elevated levels of atrial natriuretic peptide,
plasma aldosterone, plasma renin, and arginine vasopressin
all significantly decrease after VAD insertion. In the end,
these findings reflect the principle that the most effective
therapy for renal failure in these patients may be correction
of the cardiogenic shock with mechanical support.
Temporal trends in the use of VAD may also explain our
results. Although our series included patients from as early
as 1992, nearly all of our patients with severe renal dysfunc-
tion underwent VAD placement after 1994. Nearly all of
the investigations indicating poor outcomes with renal
failure included patients from the 1980s and early 1990s
(3–6). Our report, therefore, reflects a more contemporary
use of VAD than earlier reports. Increasingly, these devices
have become first-line therapies for cardiogenic shock rather
than a salvage therapy for patients who have failed conven-
tional therapy. This change in the role of VAD has made it
available to critically ill patients earlier in their illness before
the development of permanent end-organ dysfunction.
Therefore, one would expect that abnormal renal function
would have a less negative impact on outcomes in more
recent cohorts of patients. This view is supported by recently
presented data from investigators at Columbia University.
In their longitudinal study of risk factors for poor outcome
after VAD placement, renal dysfunction, which in the past
had a profound negative impact on survival, no longer
adversely affects outcomes in patients treated after 1995
(19).
CONCLUSIONS
In patients with severe renal dysfunction complicating
cardiogenic shock, early mechanical support with VAD led
to subsequent long-term recovery of renal function. Fur-
thermore, clinical outcomes including 30-day and six-
month survival, survival to transplantation, and one-year
survival after transplantation were comparable to those in
patients without severe renal dysfunction. The development
of acute renal failure should therefore not be viewed as an
absolute contraindication to the placement of a VAD as a
bridge to cardiac transplantation. In fact, its development
may identify patients with an acutely deteriorating condi-
tion that would most benefit from stabilization with early
institution of mechanical support.
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